
Results 1 - 20 of 41 in ICON
... A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 12/17/09, ICON Plc (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device ... Comment?
Dr. John Climax Announces His Retirement as Chairman of ICON plc -...
ICON Plc , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Comment?
ICON plc UK Regulatory Announcement: Dr. John Climax Announces His...
Dr. John Climax announces his retirement as Chairman of ICON plc - Dr. Bruce Given elected to succeed him Dublin, Ireland, December 17th, 2009 - ICON Plc , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Comment?
ICON Central Laboratories Expands its European Facility
ICON plc has expanded its European Central Laboratory, located in South County Business Park, Dublin. Comment?
ICON Expands Central Lab in Europe
ICON has expanded its European Central Laboratory, located in South County Business Park, Dublin. Comment?
ICON Central Laboratories Expands its European Facility to Meet Growing Demand
ICON plc, , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has expanded its European Central Laboratory, located in South County Business Park, Dublin. Comment?
"Spectacular timing" by ICON directors - the luck of the Irish?
ICON Plc founders Ronan Lambe and John Climax , as well as chief executive Peter Gray , were blessed with spectacular timing as they sold close to 10m worth of shares in the firm shortly before its shares tanked after a "warning" from the US Food and Drug Administration . Comment?
Icon bosses sell 10m shares before US 'warning'
ICON Plc founders Ronan Lambe and John Climax , as well as chief executive Peter Gray , were blessed with spectacular timing as they sold close to 10m worth of shares in the firm shortly before its shares tanked after a "warning" from the US Food and Drug Administration . Comment?
ICON Announces Details of New Translational Medicine Unit in Manchester
ICON plc, , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its new translational medicine unit in Manchester, UK. Comment?
ICON Receives Warning Letter Relating to Two Studies
Dec 4, 2009 - ICON plc, , today announced it has received a warning letter from the U.S. Food and Drug Administration regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006. Comment?
ICON receives FDA warning letter
ICON plc, , today announced it has received a warning letter from the U.S. Food and Drug Administration regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006. Comment?
ICON plc UK Regulatory Announcement: ICON Receives Warning Letter Relating to Two Studies
ICON plc, , today announced it has received a warning letter from the U.S. Food and Drug Administration regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006. Comment?
... patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. ICON plc, (NASDAQ: ICLR ) , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical ... Comment?
... decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. On 11/02/09, ICON plc, (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical ... Comment?
ICON, Lilly Extend Data Management Pact To Japan
ICON has signed an extension to its strategic agreement with Lilly to manage the company's clinical data outside the U.S. ICON will now also oversee Lilly's needs in Japan in addition to those in Europe, Canada, Latin America, Australia and Asia. Comment?
Eli Lilly selects ICON to provide clinical data management outside the US
ICON plc, , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed an extension to its strategic agreement with Eli Lilly and Company to manage the companya s clinical data management outside the US. Comment?
ICON Selected by Lilly to Oversee its Clinical Data Management in Japan
ICON plc, , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed an extension to its strategic agreement with Eli Lilly and Company to manage the company's clinical data management outside the US. Comment?
a a a 3a 3a a a 1 4a a a aa aa 1 4a Sa OEae- aeoe a a OEa 'a e aoOEa a 1 4a a c c a 'a -e -
ICON/ICLR-G Sharing Permalink Permalink To save a permanent link to this news, right-click and choose the command to copy the link, link location or shortcut. Comment?
Pharma Researchers Need a Cure
... reports followed quarterly results announced earlier this week by two other prominent CROs -- Covance (NYSE: CVD ) and Icon (Nasdaq: ICLR ) , which offered mixed results. Strategic responses CROs can't stop the revenue-rattling impact of Pfizer 's ... Comment?
Taking the Drug Industry's Temperature
... industry, research and development, can bese be measured by the health of companies such as Covance (NYSE: CVD ) and Icon (Nasdaq: ICLR ) . These contract research organizations, or CROs, conduct anything from pre-clinical tests to late-stage ... Comment?